Loading...
NPI 1275292294 · Tampa, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Elite Bio Reference Laboratory LLC is a clinical medical laboratory provider located in Tampa, Florida. This profile covers 85 Medicare and 65 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Elite Bio Reference Laboratory LLC |
| Address | 7827 N Dale Mabry Hwy Ste 100 |
| City | Tampa |
| State | FL |
| ZIP | 33614 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 17, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.6M |
| Medicaid | $167.1K |
Provider is heavily Medicare-focused: lifetime Medicare revenue is $5.6M compared with total Medicaid revenue of $167.1K, indicating Medicare dominates this provider’s payer mix and that Medicaid is a minor component of overall billed revenue. This makes the entity effectively Medicare‑driven for scale and financial exposure.
Service-line mix is weighted toward advanced molecular and genomic diagnostics with a meaningful infectious-disease testing footprint. High-revenue Medicare codes are dominated by genomic sequencing and single‑gene analysis (examples include 81419, 81302, 81185, 81321) while high-volume infectious-agent probe codes such as 87798 and respiratory panels (87631, 87502) appear throughout both payers, showing an operation that combines specialty genetic testing with routine NAAT-based infectious testing.
Revenue concentration on Medicare is significant for a few high-dollar tests: the top 3 Medicare codes by revenue account for 34.5% of total Medicare revenue, led by 81419 at $772.8K (17.7% of Medicare revenue). 81419 ranks #6 of 27 nationally and is characterized as "typical, unremarkable volume"; the other two top Medicare contributors include 87798 ($399.3K) and 81302 ($332.9K), which likewise contribute materially to the $5.6M total.
On the Medicaid side the top 3 codes account for 43.0% of Medicaid revenue, with 87798 the single largest Medicaid code at $45.7K (29.4% of Medicaid revenue). The Medicaid top codes (87798, 81238, 87481) indicate that Medicaid receipts are concentrated in high-volume, low-paid amplified-probe infectious testing and a smaller contribution from select genetic tests, and 87798’s in-state ranking is #61 of 194 with a description of "typical, unremarkable volume".
Competitive standing is mixed: the provider is not a broad national leader in overall Medicare test volume given the $5.6M scale, but it is a notable niche player on specific specialized genetic codes. It ranks #1 nationally for 81175 and #1 for 81236 (both described as "notably above typical national volume for this code"), and holds high percentile placements on several other genetic and panel codes, signaling outsized share in particular molecular assays despite modest overall scale.
There is a clear price/volume split across the code mix that shapes revenue: high-revenue genomic panels and targeted gene sequencing on the Medicare side carry large average paid per claim (for example, 81419 at $2400 avg paid/claim and 81440 at $3258 avg paid/claim), while many Medicaid entries are high-count but low‑paid infectious-disease NAAT codes (multiple entries at $2–$5 avg paid/claim). This pattern implies revenue sensitivity to reimbursement changes for a relatively small set of high-cost genomic codes, while Medicaid income is instead driven by throughput.
Operationally, the provider’s dual role—specialty genomic laboratory services plus routine amplified‑probe infectious testing—suggests a mixed business model that serves both high-margin, low-frequency genetic diagnostics and high-volume, low-margin infectious assays. That dual profile likely requires distinct workflows and payer-contracting strategies to manage both reimbursement volatility on genomic testing and volume-driven margins on infectious testing.
Tenure is relatively short: NPI was enumerated on 2021-12-17 (~5 years ago). Accumulating $5.6M in Medicare revenue and a broad list of specialized genomic CPTs since enumeration suggests rapid scaling into molecular/genetic testing niches over a short operating window.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
85 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 320 | $2,400 | $772.8K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 11,740 | $30 | $399.3K |
| 81302 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the methyl CpG binding protein 2, or MECP2 gene. | 640 | $520 | $332.9K |
| 81185 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the calcium voltage–gated channel subunit alpha1 A gene, also called CACNA1A. | 390 | $830 | $320.8K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 430 | $590 | $252.3K |
| 81325 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the peripheral myelin protein 22, or PMP22, gene. | 330 | $750 | $248.8K |
| 81175 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the additional sex combs like 1 (ASXL1), transcriptional regulator gene. | 330 | $660 | $220.1K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 350 | $580 | $204.4K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 350 | $490 | $169.8K |
| 81286 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the frataxin gene (FXN). | 550 | $270 | $147.1K |
Showing 1–10 of 85
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 85 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
85 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81440 | 6 | 10 | 170 | $3,240 | $658.4K |
| 81307 | 17 | 30 | 320 | $660 | $508.3K |
| 81443 | 7 | 10 | 170 | $2,400 | $481.7K |
| 81321 | 13 | 30 | 430 | $580 | $467.7K |
| 81238 | 11 | 20 | 330 | $590 | $440.3K |
| 81419 | 2 | 10 | 90 | $2,400 | $434.1K |
| 81249 | 13 | 20 | 290 | $590 | $383.1K |
| 81223 | 11 | 20 | 340 | $490 | $329.3K |
| 81351 | 15 | 20 | 210 | $630 | $307.8K |
| 87798 | 8 | 110 | 590 | $30 | $218.6K |
Showing 1–10 of 85
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
65 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1,900 | $20 | $45.7K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 100 | $110 | $11.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 1,890 | $10 | $9.4K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 50 | $180 | $8.8K |
| 81286 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the frataxin gene (FXN). | 200 | $40 | $7.9K |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 80 | $90 | $6.8K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 90 | $70 | $6.1K |
| 81345 | The lab analyst performs the technical lab test to analyze targeted genes, such as the promotor region for the telomerase reverse transcriptase gene (TERT). | 150 | $40 | $5.9K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,360 | $1 | $5.4K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 1,340 | $1 | $4K |
Showing 1–10 of 65
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
65 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 35 | 40 | 320 | $100 | $620K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 280 | 320 | 750 | $40 | $232.7K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 82 | 90 | 320 | $20 | $100.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 414 | 450 | 1,380 | $20 | $75.1K |
| 81329 | The lab analyst performs the technical lab test to detect deletions in the survival of motor neuron 1 (SMN1), telomeric, gene and may also analyze the survival of motor neuron 2 (SMN2), centromeric,… | 10 | 10 | 200 | $20 | $72K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 35 | 110 | 490 | $40 | $64.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 61 | 190 | 640 | $10 | $59.9K |
| 81243 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for fragile X messenger ribonucleoprotein 1, also known as FMR1, typically to detect common abnormal… | 12 | 10 | 80 | $10 | $42.6K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 54 | 190 | 420 | $20 | $40.4K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 28 | 40 | 230 | $60 | $38.5K |
Showing 1–10 of 65
Other providers in the same ZIP code as Elite Bio Reference Laboratory LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Etairos Health, Inc | FL | In Home Supportive Care Agency | $0 | $14.4M |
| Mark Le | FL | Diagnostic Radiology Physician | $10.7M | $0 |
| University Community Hospital, Inc | FL | General Acute Care Hospital | $0 | $10.3M |
| Fi-tampa, LLC | FL | Skilled Nursing Facility | $0 | $9.5M |
| Loving Home Care Services, Inc. | FL | Home Health Agency | $0 | $9.2M |
| Caremark, L.L.C. | FL | Specialty Pharmacy | $1.1M | $7.3M |
| Allure Home Health Corp | FL | Home Health Agency | $0 | $7.7M |
| Jesse Mccann | FL | Retina Specialist (Ophthalmology) Physician | $2M | $0 |
| Philip Atigre | FL | Internal Medicine Physician | $679.8K | $0 |
| Thomas Kerr | FL | Vascular Surgery Physician | $634.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.